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Objective: To investage the mRNA expression level of HIF1α and 
XRCC4 in non-small-cell lung cancer samples and peritumoral normal 
lung tussie and to evaluate their pronostic value. 
Methods: 29 non small cell lung cancer patients who had received the 
curative operation and adjuvant thoracic radiotherapy were included in 
this study. mRNA expression level of HIF1α and XRCC4 in congelated 
tumor samples and peritumoral normal tissue were detemined using 
real time RT-PCR method. Relationship of the expression level of the 
target genes and the clinic parameters and disease-free survival (DFS) 
of the patients were analysed. 
Results: the patients with high expression level of HIF1α mRNA in 
tumor tissue had relatively long DFS but statistically not signiﬁcative. 
The patients with low expression of HIF1α mRNA in peritumoral nor-
mal tissue had a longer DFS (median 26 months) than high expres-
sion’s group (median 10 months, p=0.028). The ratio of tumor/normal 
tissue expression of HIF1α could further distinguish the patients with 
different DFS. Expression of XRCC4 in tumor or peripherical normal 
tissue did not correlate with the patients’ DFS. 
Conclusion: The HIF1α mRNA expression in peritumoral normal tis-
sue and the ratio of tumor/normal tissue expression of HIF1α may be a 
prognostic factor in non small cell lung cancer. 
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Prognostic significance of COX-2 and VEGF expression in lung 
cancer
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Aim: In lung cancer patients, detecting the expression of various tumor 
markers are seem to be important for both the evaluation of prognosis, 
and management of treatment. In this study, we aimed to evaluate the 
expressions degree of COX2 (cyclooxygenase-2) and VEGF (vascular 
endothelial growth factor) in bronchoscopic biopsy tissues of patients 
with lung cancer and the relationship with survival.
Method: In this study, we evaluate 125 patients in three groups: Sev-
enty patients were diagnosed by bronchoscopic biopsy (1st group), 22 
patients were diagnosed by a method other than bronchoscopic biopsy 
(2nd group) and 33 patients were diagnosed as benign lung diseases 
by bronchoscopy (control group) were included. COX2 and VEGF 
expressions were evaluated by immunohistochemical method in bron-
choscopic biopsy specimen. These specimens were scored according to 
staining intensity and densities. Scores, greater than 2, were accepted 
as positive.
Table 1 Patients characteristics 
Patient’s characteristics Group 1 Group 2 Group 3
Median age 60.0 57.5 47.0
(Min - Max) (39-80) (35-78) (15-78)
Gender Male/Female (n) 64/6 22/0 14/19
Performance Status 
Good/Poor (n) 53/17 15/7 -/-
NSCLC 
(IIB-IIIA) / (IIIB-IV) (n) 11/40 1/19 -/-
Squa./Adeno/Undiﬀ. (n) 29/12/10 5/5/10 -/-
SCLC 
Limited / Extensive (n) 7/12 2/0 -/-
COX-2 and VEGF expressions were also evaluated according to histological cell types, stages and 
performance status. 
Results: COX2 expression was found signiﬁcantly higher in group 1 
than group 2 and group 3 (p=0,027 and p=0,001 respectively). At the 
subgroup analysis, similarly COX2 expression was found to be higher 
in the 1st group than the control group in small cell carcinoma (SCLC) 
and non-small cell carcinoma (NSCLC) patients (p=0.001 and p=0.006 
respectively). COX2 expression was also found higher at the 1st group 
than the controls in the adenocarcinoma and epidermoid carcinoma 
patients (p=0.017 and p=0.006 respectively). However, VEGF expres-
sions of patients with advanced stages (stages IIIB-IV) were greater 
than the patients with early stages (stages IIB-IIIA) in NSCLC patients 
(p=0.014, OR=4.8(1.28-17.89, 95%CI)). At the survival analysis, there 
was a statistically signiﬁcant correlation between VEGF expression and 
shorter overall survival in all patients and also in NSCLC (p<0.01 and 
p=0.03 respectively). 
Conclusion: Our study results suggest that COX2 expression might 
be used as a diagnostic marker, while VEGF expression might be a 
prognostic marker in patients with lung cancer.
